758 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
GSK GlaxoSmithKline PLC $40.58 $99.79B Sell
Article Searches
Stocks To Watch: Any Privacy For Tesla? https://seekingalpha.com/article/4197968-stocks-watch-privacy-tesla?source=feed Aug 11, 2018 - Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
U.S. Moats Ahead Despite IT Underweight https://seekingalpha.com/article/4196944-u-s-moats-ahead-despite-underweight?source=feed_tag_etf_portfolio_strategy Aug 09, 2018 - For the month Ending July 30, 2018 Performance Overview Domestic moat companies, as represented by the Morningstar Wide Moat Focus IndexSM (MWMFTR, or U.S. Moat Index), once again posted strong result
Aridis Pharmaceuticals Readies $28 Million IPO https://seekingalpha.com/article/4196090-aridis-pharmaceuticals-readies-28-million-ipo?source=feed_tag_ipo_analysis Aug 07, 2018 -
Stocks making the biggest moves premarket: CI, BHC, MNK, DF, MAR, Z & more https://www.cnbc.com/2018/08/07/stocks-making-the-biggest-moves-premarket-ci-bhc-mnk-df-mar-z--.html Aug 07, 2018 - Names on the move ahead of the open.
GlaxoSmithKline's (GSK) CEO Emma Walmsley on Q2 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4190095-glaxosmithklines-gsk-ceo-emma-walmsley-q2-2018-results-earnings-call-transcript?source=feed_sector_healthcare Jul 25, 2018 - GlaxoSmithKline plc (NYSE:GSK) Q2 2018 Results Earnings Conference Call July 25, 2018, 9:15 AM ET Executives Emma Walmsley - Chief Executive Officer Luke Miels - President, Global Pharmaceuticals Simo
GlaxoSmithKline 2018 Q2 - Results - Earnings Call Slides https://seekingalpha.com/article/4190028-glaxosmithkline-2018-q2-results-earnings-call-slides?source=feed_sector_healthcare Jul 25, 2018 - The following slide deck was published by GlaxoSmithKline in conjunction with their 2018 Q2 earnings call.
$300M DNA play: GSK to collaborate with 23andMe on genetics-driven drug discovery http://feeds.bizjournals.com/~r/industry_6/~3/TMhb3d5AKiA/300m-dna-play-gsk-to-collaborate-with-23andme-on.html Jul 25, 2018 - GlaxoSmithKline is taking a deeper dive into genetics, with a large investment in Mountain View, California-based genetic profiling company 23andMe and a new approach to research and development. The London-based pharmaceutical giant, which has operations in Research Triangle Park, entered into a 4-year, $300 million collaboration with 23andMe that will focus on new medicines and potential cures for diseases – using human genetics as the basis for discovery. The $300 million represents an equity…
$300M DNA play: GSK collaborates with 23andMe http://feeds.bizjournals.com/~r/industry_6/~3/V4xIfVYxLsM/300m-dna-play-gsk-collaborates-with-23andme.html Jul 25, 2018 - GlaxoSmithKline is taking a deeper dive into genetics, with a large investment in a genetic profiling company and a new approach to research and development. The London-based pharmaceutical giant has entered into a four-year, $300 million collaboration with 23andMe that will focus on new medicines and potential cures for diseases – using human genetics as the basis for discovery. The $300 million represents an equity investment GSK is making in 23andMe. Based in Mountain View, Calif., 23andMe…
GlaxoSmithKline Achieves Successful 2-Drug Regimen Studies For HIV, Gilead Might Have Met Its Match https://seekingalpha.com/article/4189798-glaxosmithkline-achieves-successful-2-drug-regimen-studies-hiv-gilead-might-met-match?source=feed_sector_healthcare Jul 25, 2018 - GlaxoSmithKline obtains positive results in treating patients with HIV from two duplicate phase 3 studies. The two-drug HIV regimen from GlaxoSmithKline's dolutegravir and lamivudine achieved closely
Merck's Keytruda Improves Survival in Head/Neck Cancer Study http://www.zacks.com/stock/news/313380/mercks-keytruda-improves-survival-in-head-neck-cancer-study?cid=CS-ZC-FT-313380 Jul 25, 2018 - Merck's (MRK) key cancer drug Keytruda succeeds as a monotherapy in phase III program. It is being evaluated for the first-line treatment of patients with advanced head and neck cancer.

Pages: 123456...76

Page 1>

Related Companies

Name Exchange Price Mkt Cap
BMY Bristol-Myers Squibb Company NYSE $63.36 $103.91B
LLY Eli Lilly and Company NYSE $83.91 $92.38B
ABT Abbott Laboratories NYSE $52.51 $91.23B
CELG Celgene Corporation NASDAQ $143.91 $112.59B
AZN Astrazeneca PLC NYSE $33.95 $85.96B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for GlaxoSmithKline PLC